Skip to content

Study · Animal study (in vivo) · mouse · 2002

3 results

Effect of epithalon on the incidence of chromosome aberrations in senescence-accelerated mice.

Rosenfeld SV, Togo EF, Mikheev VS, Popovich IG, Khavinson VKh, Anisimov VN

Bulletin of experimental biology and medicine1 Mar 2002Cited by 7 (Europe PMC)

PMID12360351 (opens in a new tab)DOI10.1023/a:1015899003974 (opens in a new tab)PepBankPUB-12360351
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In SAMP-1 senescence-accelerated mice, Epithalon decreased the incidence of chromosome aberrations by 20% compared with age-matched controls.

    In plain wordsIn aging-prone mice, Epithalon lowered chromosome damage in bone marrow cells compared with age-matched controls.

    Peptide
    Epitalon
    Outcome
    DecreaseChromosome aberrations in bone marrow cells, SAMP-1 mice
    Study

    mousen: not reported in source

    SAMP-1 senescence-accelerated mice
    Comparator
    Age-matched controls
    Outcome group
    Aging markers · Aging and longevity
    Studied dose
    Dose not stated · from the age of 2 monthsAs given in this study (mouse).

    Measurements

    Reduction in chromosome aberrations
    20%
    SAMP-1

    Source sentences

    Summary
    Treatment with Epithalon (Ala-Glu-Asp-Gly) starting from the age of 2 months decreased the incidence of chromosome aberrations in SAMP-1, SAMR-1, and SHR mice by 20%, 30.1%, and 17.9%, respectively, compared to age-matched controls (p<0.05).
    1 context sentence
    Summary · context
    The incidence of chromosome aberrations in bone marrow cells of 12-month-old SAMP-1 female mice characterized by accelerated aging was 1.8 times higher than in wild-type SAMR-1 females and 2.2 times higher than in SHR females of the same age.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In SAMR-1 mice, Epithalon decreased the incidence of chromosome aberrations by 30.1% compared with age-matched controls.

    In plain wordsIn normally aging mice, Epithalon lowered chromosome damage in bone marrow cells compared with age-matched controls.

    Peptide
    Epitalon
    Outcome
    DecreaseChromosome aberrations in bone marrow cells, SAMR-1 mice
    Study

    mousen: not reported in source

    SAMR-1 wild-type mice
    Comparator
    Age-matched controls
    Outcome group
    Aging markers · Aging and longevity
    Studied dose
    Dose not stated · from the age of 2 monthsAs given in this study (mouse).

    Measurements

    Reduction in chromosome aberrations
    30.1%
    SAMR-1

    Source sentences

    Summary
    Treatment with Epithalon (Ala-Glu-Asp-Gly) starting from the age of 2 months decreased the incidence of chromosome aberrations in SAMP-1, SAMR-1, and SHR mice by 20%, 30.1%, and 17.9%, respectively, compared to age-matched controls (p<0.05).
    1 context sentence
    Summary · context
    The incidence of chromosome aberrations in bone marrow cells of 12-month-old SAMP-1 female mice characterized by accelerated aging was 1.8 times higher than in wild-type SAMR-1 females and 2.2 times higher than in SHR females of the same age.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In SHR mice, Epithalon decreased the incidence of chromosome aberrations by 17.9% compared with age-matched controls.

    In plain wordsIn SHR mice, Epithalon lowered chromosome damage in bone marrow cells compared with age-matched controls.

    Peptide
    Epitalon
    Outcome
    DecreaseChromosome aberrations in bone marrow cells, SHR mice
    Study

    mousen: not reported in source

    SHR mice
    Comparator
    Age-matched controls
    Outcome group
    Aging markers · Aging and longevity
    Studied dose
    Dose not stated · from the age of 2 monthsAs given in this study (mouse).

    Measurements

    Reduction in chromosome aberrations
    17.9%
    SHR

    Source sentences

    Summary
    Treatment with Epithalon (Ala-Glu-Asp-Gly) starting from the age of 2 months decreased the incidence of chromosome aberrations in SAMP-1, SAMR-1, and SHR mice by 20%, 30.1%, and 17.9%, respectively, compared to age-matched controls (p<0.05).
    1 context sentence
    Summary · context
    The incidence of chromosome aberrations in bone marrow cells of 12-month-old SAMP-1 female mice characterized by accelerated aging was 1.8 times higher than in wild-type SAMR-1 females and 2.2 times higher than in SHR females of the same age.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.